Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus

J Rheumatol. 2003 Sep;30(9):1977-82.


Objective: To develop a measurement of lupus disease activity over time.

Methods: We studied patients from the University of Toronto Lupus Clinic with "regular" followup, defined as having been in the clinic for at least 3 visits and never having been away from the clinic for a period exceeding 18 consecutive months. For each visit, disease activity was evaluated with the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). The common approach to summarize over multiple visits by calculating a mean ignores the presence of varying time intervals between visits. We used the adjusted mean SLEDAI-2K (AMS), determined by the calculation of the area under the curve of SLEDAI-2K over time by adding the area of each of the blocks of visit interval and then dividing by the length of time for the whole period. The resulting AMS has the same units as the original SLEDAI-2K. A time-dependent covariate survival analysis was done to test which of AMS, SLEDAI-2K at presentation, sex, and age at diagnosis is the best predictor of mortality.

Results: A total of 575 patients with regular followup were included. Only AMS and age at diagnosis were significant predictors. Odds ratio (OR) and 95% confidence intervals (CI) for AMS: OR 1.15 (CI 1.09, 1.20), p = 0.0001; age at diagnosis: OR 1.05 (CI 1.03, 1.06), p = 0.0001.

Conclusion: AMS represents an average disease activity measure over time and is strongly associated with mortality.

Publication types

  • Comparative Study

MeSH terms

  • Adolescent
  • Adult
  • Age Factors
  • Age of Onset
  • Aged
  • Aged, 80 and over
  • Cause of Death*
  • Child
  • Child, Preschool
  • Cohort Studies
  • Confidence Intervals
  • Disease Progression
  • Female
  • Health Status
  • Humans
  • Life
  • Life Expectancy*
  • Lupus Erythematosus, Systemic / diagnosis*
  • Lupus Erythematosus, Systemic / drug therapy
  • Lupus Erythematosus, Systemic / mortality*
  • Male
  • Middle Aged
  • Odds Ratio
  • Ontario
  • Predictive Value of Tests
  • ROC Curve
  • Risk Assessment
  • Severity of Illness Index
  • Sex Factors
  • Sickness Impact Profile*
  • Survival Analysis
  • Time Factors